Rubicon Research Limited

Rubicon Research Limited, established on May 6, 1999, is a publicly listed pharmaceutical company headquartered in Thane, Maharashtra, India. The company specializes in the development, manufacturing, and commercialization of generic and specialty pharmaceutical formulations. Its product portfolio spans various therapeutic categories, including cardiovascular, central nervous system (CNS), and antimalarial treatments. Rubicon Research Limited is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 544578 and on the National Stock Exchange of India (NSE) under the ticker symbol RUBICON.

The company's authorized capital is ₹23.90 crore, with a paid-up capital of ₹16.48 crore. As of the latest available data, Rubicon Research Limited employs approximately 827 professionals. The corporate office is located at MedOne House, B-75, Road No. 33, Wagle Estate, Thane (West), Maharashtra 400604, India.

Rubicon Research Limited operates multiple manufacturing facilities in India, including plants in Ambernath, Satara, and Pithampur. The Ambernath facility, commissioned in 2009, specializes in the production of oral solid dosage forms. In 2021, the company acquired the oral liquid dosage and nasal product manufacturing facility of Meditab Specialities Limited in Satara, Maharashtra. Additionally, in 2025, Rubicon Research Limited acquired the Pithampur manufacturing facility from Alkem Laboratories Ltd.

The leadership team at Rubicon Research Limited includes:

• Parag Suganchand Sancheti: Chief Executive Officer (CEO) since May 9, 2019.

• Pratibha Sudhir Pilgaonkar: Managing Director since June 1, 2000.

• Anand Agarwal: Nominee Director since January 3, 2025.

• Changavalli Venkat: Director since June 11, 2024.

• Varun Talukdar: Director since September 5, 2023.

Rubicon Research Limited has established a significant presence in regulated markets, particularly in the United States. The company has obtained Good Manufacturing Practice (GMP) certifications for its facilities in Ambernath and Satara, Maharashtra, enabling it to manufacture and export pharmaceutical products to the U.S. and European markets. Additionally, Rubicon Research Limited has received approvals for over 28 products in the U.S. market, demonstrating its compliance with stringent regulatory standards.

Rubicon Research Limited has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's acquisition of Impopharma Canada Ltd. in 2019, which specializes in pulmonary and nasal drug delivery systems, ophthalmic, otic, and dermal products, has enhanced its capabilities to serve these regions. Furthermore, the establishment of Rubicon Consumer Healthcare in 2020 indicates a strategic focus on developing healthcare and personal wellness solutions tailored for the Indian market.

Rubicon Research Limited's geographic strategy reflects a balanced approach to market diversification and risk management. The company's significant export value of $11.1 million USD across 357 shipments, with a portfolio concentration of 93% in its top five products, indicates a focused yet diversified product strategy. The therapeutic categories of cardiovascular, CNS & psychiatric, and antimalarial & antiparasitic align with global health priorities, positioning the company to leverage opportunities in both developed and emerging markets.

Rubicon Research Limited's manufacturing facilities in Ambernath and Satara, Maharashtra, are registered with the U.S. Food and Drug Administration (FDA), allowing the company to export pharmaceutical products to the U.S. market. The company has received approvals for over 28 products in the U.S., demonstrating its compliance with FDA standards. Additionally, Rubicon Research Limited has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, reflecting its commitment to expanding its product offerings in the U.S. market.

Rubicon Research Limited's manufacturing facilities have been inspected and approved by the World Health Organization (WHO) and the European Medicines Agency (EMA), ensuring compliance with international Good Manufacturing Practice (GMP) standards. These certifications facilitate the company's ability to export pharmaceutical products to various global markets, including Europe and other regions that recognize WHO and EU GMP standards.

Rubicon Research Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's facilities in Ambernath and Satara, Maharashtra, are approved by the CDSCO, enabling the production and distribution of pharmaceutical products within India. Additionally, Rubicon Research Limited has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), authorizing the export of its products to international markets.

As of March 28, 2026, there are no publicly available records indicating that Rubicon Research Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities such as the FDA. This absence suggests that the company maintains a strong compliance record with regulatory standards.

Rubicon Research Limited operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's focus on specialized drug delivery technologies and a diverse product portfolio positions it favorably against competitors. The acquisition of Impopharma Canada Ltd. and the establishment of subsidiaries like Rubicon Consumer Healthcare and Rubicon Academy further enhance its competitive edge by expanding its product offerings and market reach.

Rubicon Research Limited's key differentiators include its proprietary drug delivery technologies, such as RubiSRL for sustained release liquids and RubiReten for gastro-retentive systems. The company's extensive patent portfolio, with over 50 patents in drug delivery technologies, underscores its commitment to innovation. Additionally, the acquisition of Impopharma Canada Ltd. has expanded its capabilities in pulmonary and nasal drug delivery systems, ophthalmic, otic, and dermal products, further distinguishing its product offerings.

Rubicon Research Limited's current strategic direction focuses on the development of generic and specialty pharmaceutical formulations, with an emphasis on complex drug delivery systems. The company's expansion into emerging markets and the establishment of subsidiaries like Rubicon Consumer Healthcare indicate a strategic intent to diversify its product offerings and market presence. Looking ahead, Rubicon Research Limited is well-positioned to leverage its innovative capabilities and global manufacturing footprint to capitalize on growth opportunities in both developed and emerging markets.

Rubicon Research Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $11.1 million USD across 357 shipments. The company's portfolio concentration of 93% in its top five products indicates a focused approach to product development and market penetration. The absence of regulatory observations or warnings further attests to its reliability as a supplier. These factors collectively suggest that Rubicon Research Limited is a dependable partner for pharmaceutical procurement.

Importers should verify the following certifications when considering Rubicon Research Limited as a supplier:

• FDA Registration: Confirm the registration of manufacturing facilities with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure that manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice standards.

• EU GMP Certification: Verify compliance with the European Medicines Agency's Good Manufacturing Practice standards.

• ISO Certifications: Check for relevant International Organization for Standardization certifications related to quality management systems.

These certifications can typically be verified through official regulatory bodies or by requesting documentation directly from Rubicon Research Limited.